Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard? View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2015-04-18

AUTHORS

Isaac Melguizo-Gavilanes, Janet M. Bruner, Nandita Guha-Thakurta, Kenneth R. Hess, Vinay K. Puduvalli

ABSTRACT

Pseudoprogression (psPD) refers to an increase in size or appearance of new areas of MRI contrast enhancement soon after completing chemoradiation, timely diagnosis of which has been a challenge. Given that tissue sampling of the MRI changes would be expected to accurately distinguish psPD from true progression when MRI changes are first seen, we examined the utility of surgery in diagnosing psPD and influencing patient outcome. We retrospectively reviewed data from adults with GBM who had MRI changes suggestive of progression within 3 months of chemoRT; of these, 34 underwent surgical resection. Three subsets–tumor, psPD or mixed-were identified based on histology and immunohistochemistry in the surgical group and by imaging characteristics in the nonsurgical group. A cohort of patients with stable disease post-chemoRT served as control. PFS and OS were determined using the Kaplan–Meier method and log rank analysis. Concordance for psPD between radiological interpretation and subsequent histological diagnosis was seen in only 32 % of cases (11/34) 95 %CI 19–49 %. A large proportion of patients had a histologically “mixed” pattern with tumor and treatment effect. No significant differences in PFS or OS were seen among the three subtypes. Surgical sampling and histologic review of MRI changes after chemoRT may not serve as a gold standard to distinguish psPD from true progression in GBM patients. Refinement of the histological criteria, careful intraoperative selection of regions of interest and advanced imaging modalities are needed for early differentiation of PsPD from progression to guide clinical management. More... »

PAGES

141-150

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11060-015-1774-5

DOI

http://dx.doi.org/10.1007/s11060-015-1774-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1018898395

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25894594


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Brain Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemoradiotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glioblastoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunoenzyme Techniques", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Magnetic Resonance Imaging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Neuro-Oncology Associates at Baylor Charles A. Sammons Cancer Center, 75246, Dallas, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.486749.0", 
          "name": [
            "Neuro-Oncology Associates at Baylor Charles A. Sammons Cancer Center, 75246, Dallas, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Melguizo-Gavilanes", 
        "givenName": "Isaac", 
        "id": "sg:person.01013322710.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013322710.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bruner", 
        "givenName": "Janet M.", 
        "id": "sg:person.013375073077.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013375073077.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Radiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guha-Thakurta", 
        "givenName": "Nandita", 
        "id": "sg:person.01071535250.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071535250.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hess", 
        "givenName": "Kenneth R.", 
        "id": "sg:person.010260560177.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010260560177.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Neuro-oncology, The Ohio State University Comprehensive Cancer Center, 320 W, 10th Ave, M410 Staling Loving Hall, 43210, Columbus, OH, USA", 
          "id": "http://www.grid.ac/institutes/grid.261331.4", 
          "name": [
            "Division of Neuro-oncology, The Ohio State University Comprehensive Cancer Center, 320 W, 10th Ave, M410 Staling Loving Hall, 43210, Columbus, OH, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Puduvalli", 
        "givenName": "Vinay K.", 
        "id": "sg:person.01156403355.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156403355.42"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10014-012-0109-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012468803", 
          "https://doi.org/10.1007/s10014-012-0109-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-007-9341-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000374634", 
          "https://doi.org/10.1007/s11060-007-9341-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-009-9897-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030107392", 
          "https://doi.org/10.1007/s11060-009-9897-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11910-009-0035-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052174107", 
          "https://doi.org/10.1007/s11910-009-0035-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00401-005-0023-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019017045", 
          "https://doi.org/10.1007/s00401-005-0023-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-009-9809-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004320007", 
          "https://doi.org/10.1007/s11060-009-9809-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-006-9241-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015983460", 
          "https://doi.org/10.1007/s11060-006-9241-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-005-5262-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031267961", 
          "https://doi.org/10.1007/s11060-005-5262-1"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-04-18", 
    "datePublishedReg": "2015-04-18", 
    "description": "Abstract\n\nPseudoprogression (psPD) refers to an increase in size or appearance of new areas of MRI contrast enhancement soon after completing chemoradiation, timely diagnosis of which has been a challenge. Given that tissue sampling of the MRI changes would be expected to accurately distinguish psPD from true progression when MRI changes are first seen, we examined the utility of surgery in diagnosing psPD and influencing patient outcome. We retrospectively reviewed data from adults with GBM who had MRI changes suggestive of progression within 3\u00a0months of chemoRT; of these, 34 underwent surgical resection. Three subsets\u2013tumor, psPD or mixed-were identified based on histology and immunohistochemistry in the surgical group and by imaging characteristics in the nonsurgical group. A cohort of patients with stable disease post-chemoRT served as control. PFS and OS were determined using the Kaplan\u2013Meier method and log rank analysis. Concordance for psPD between radiological interpretation and subsequent histological diagnosis was seen in only 32\u00a0% of cases (11/34) 95\u00a0%CI 19\u201349\u00a0%. A large proportion of patients had a histologically \u201cmixed\u201d pattern with tumor and treatment effect. No significant differences in PFS or OS were seen among the three subtypes. Surgical sampling and histologic review of MRI changes after chemoRT may not serve as a gold standard to distinguish psPD from true progression in GBM patients. Refinement of the histological criteria, careful intraoperative selection of regions of interest and advanced imaging modalities are needed for early differentiation of PsPD from progression to guide clinical management.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11060-015-1774-5", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2420949", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2438826", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1094205", 
        "issn": [
          "0167-594X", 
          "1573-7373"
        ], 
        "name": "Journal of Neuro-Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "123"
      }
    ], 
    "keywords": [
      "MRI changes", 
      "true progression", 
      "utility of surgery", 
      "cohort of patients", 
      "Kaplan-Meier method", 
      "log-rank analysis", 
      "gold standard", 
      "subsequent histological diagnosis", 
      "advanced imaging modalities", 
      "nonsurgical group", 
      "surgical resection", 
      "surgical group", 
      "histological diagnosis", 
      "histologic review", 
      "surgical sampling", 
      "clinical management", 
      "patient outcomes", 
      "timely diagnosis", 
      "histological criteria", 
      "GBM patients", 
      "intraoperative selection", 
      "patients", 
      "radiological interpretation", 
      "progression", 
      "imaging modalities", 
      "chemoRT", 
      "treatment effects", 
      "pseudoprogression", 
      "significant differences", 
      "PFS", 
      "contrast enhancement", 
      "histology", 
      "MRI contrast enhancement", 
      "PsPD", 
      "diagnosis", 
      "cases 95", 
      "early differentiation", 
      "rank analysis", 
      "large proportion", 
      "chemoradiation", 
      "OS", 
      "resection", 
      "surgery", 
      "group", 
      "immunohistochemistry", 
      "cohort", 
      "tumors", 
      "cis-19", 
      "subtypes", 
      "glioblastoma", 
      "months", 
      "adults", 
      "outcomes", 
      "GBM", 
      "modalities", 
      "tissue", 
      "changes", 
      "concordance", 
      "review", 
      "proportion", 
      "differentiation", 
      "management", 
      "differences", 
      "control", 
      "criteria", 
      "appearance", 
      "standards", 
      "increase", 
      "utility", 
      "effect", 
      "patterns", 
      "data", 
      "sampling", 
      "new areas", 
      "analysis", 
      "area", 
      "challenges", 
      "characteristics", 
      "region", 
      "enhancement", 
      "Abstract", 
      "size", 
      "selection", 
      "method", 
      "interest", 
      "characterization", 
      "interpretation", 
      "refinement"
    ], 
    "name": "Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?", 
    "pagination": "141-150", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1018898395"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11060-015-1774-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25894594"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11060-015-1774-5", 
      "https://app.dimensions.ai/details/publication/pub.1018898395"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:31", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_677.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11060-015-1774-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11060-015-1774-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11060-015-1774-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11060-015-1774-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11060-015-1774-5'


 

This table displays all metadata directly associated to this object as RDF triples.

300 TRIPLES      22 PREDICATES      141 URIs      125 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11060-015-1774-5 schema:about N14276f34da4847598b63ca638e76fbad
2 N15478276d80347f9bbcbe437e9da903a
3 N2f528f55a3584fba83dbafa2490cd4c9
4 N361d316fe14142dbbe132728e5de428f
5 N3c201564abc848dda8d27345e059b373
6 N3ecdf3c88da34d499f82a371e789882e
7 N3f6f08b1fc654547813e6f78c253097d
8 N48c930dd861a428ab74fac7148ae53d1
9 N50fcc5de88de4ea1adeb039beca7e93f
10 N608eeb3184734bb5a88c1e6aac40a8d2
11 N6a192e25b2b44dce9781ac840bbe8125
12 N711ea13cd48a4ef48259072b91e50b46
13 N72a0936cae264bd49bd65f6a20f539ec
14 N75f01a15587d40628242c76f0498cc0e
15 N8edfb53422ef42fd98093d2feacb245c
16 Na0b8e0cbac88492f8b1a4890c93c36d3
17 Na989d2dd343441f69e01f7fd3142d855
18 Nac5d0a0ee33b4c53afafd7582210997b
19 Nac7d1e319e7b491ab992bd4396232c09
20 anzsrc-for:11
21 anzsrc-for:1103
22 schema:author N568c761cf6e24ab5a3ff5faf12ef739e
23 schema:citation sg:pub.10.1007/s00401-005-0023-y
24 sg:pub.10.1007/s10014-012-0109-x
25 sg:pub.10.1007/s11060-005-5262-1
26 sg:pub.10.1007/s11060-006-9241-y
27 sg:pub.10.1007/s11060-007-9341-3
28 sg:pub.10.1007/s11060-009-9809-4
29 sg:pub.10.1007/s11060-009-9897-1
30 sg:pub.10.1007/s11910-009-0035-4
31 schema:datePublished 2015-04-18
32 schema:datePublishedReg 2015-04-18
33 schema:description Abstract Pseudoprogression (psPD) refers to an increase in size or appearance of new areas of MRI contrast enhancement soon after completing chemoradiation, timely diagnosis of which has been a challenge. Given that tissue sampling of the MRI changes would be expected to accurately distinguish psPD from true progression when MRI changes are first seen, we examined the utility of surgery in diagnosing psPD and influencing patient outcome. We retrospectively reviewed data from adults with GBM who had MRI changes suggestive of progression within 3 months of chemoRT; of these, 34 underwent surgical resection. Three subsets–tumor, psPD or mixed-were identified based on histology and immunohistochemistry in the surgical group and by imaging characteristics in the nonsurgical group. A cohort of patients with stable disease post-chemoRT served as control. PFS and OS were determined using the Kaplan–Meier method and log rank analysis. Concordance for psPD between radiological interpretation and subsequent histological diagnosis was seen in only 32 % of cases (11/34) 95 %CI 19–49 %. A large proportion of patients had a histologically “mixed” pattern with tumor and treatment effect. No significant differences in PFS or OS were seen among the three subtypes. Surgical sampling and histologic review of MRI changes after chemoRT may not serve as a gold standard to distinguish psPD from true progression in GBM patients. Refinement of the histological criteria, careful intraoperative selection of regions of interest and advanced imaging modalities are needed for early differentiation of PsPD from progression to guide clinical management.
34 schema:genre article
35 schema:inLanguage en
36 schema:isAccessibleForFree true
37 schema:isPartOf N540b69c23e434c1d91efb0e0a74a3cfa
38 N86636079bd784e47984652d7978c143b
39 sg:journal.1094205
40 schema:keywords Abstract
41 GBM
42 GBM patients
43 Kaplan-Meier method
44 MRI changes
45 MRI contrast enhancement
46 OS
47 PFS
48 PsPD
49 adults
50 advanced imaging modalities
51 analysis
52 appearance
53 area
54 cases 95
55 challenges
56 changes
57 characteristics
58 characterization
59 chemoRT
60 chemoradiation
61 cis-19
62 clinical management
63 cohort
64 cohort of patients
65 concordance
66 contrast enhancement
67 control
68 criteria
69 data
70 diagnosis
71 differences
72 differentiation
73 early differentiation
74 effect
75 enhancement
76 glioblastoma
77 gold standard
78 group
79 histologic review
80 histological criteria
81 histological diagnosis
82 histology
83 imaging modalities
84 immunohistochemistry
85 increase
86 interest
87 interpretation
88 intraoperative selection
89 large proportion
90 log-rank analysis
91 management
92 method
93 modalities
94 months
95 new areas
96 nonsurgical group
97 outcomes
98 patient outcomes
99 patients
100 patterns
101 progression
102 proportion
103 pseudoprogression
104 radiological interpretation
105 rank analysis
106 refinement
107 region
108 resection
109 review
110 sampling
111 selection
112 significant differences
113 size
114 standards
115 subsequent histological diagnosis
116 subtypes
117 surgery
118 surgical group
119 surgical resection
120 surgical sampling
121 timely diagnosis
122 tissue
123 treatment effects
124 true progression
125 tumors
126 utility
127 utility of surgery
128 schema:name Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?
129 schema:pagination 141-150
130 schema:productId N071e1bca21494030a33a65ca7375f10b
131 N26342b2c745a47498f761c7393b7395b
132 N4dd73f8438eb41578917d565d0eb50e5
133 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018898395
134 https://doi.org/10.1007/s11060-015-1774-5
135 schema:sdDatePublished 2022-05-20T07:31
136 schema:sdLicense https://scigraph.springernature.com/explorer/license/
137 schema:sdPublisher Neb09d3aa1f504e87b462a1df8b92fe29
138 schema:url https://doi.org/10.1007/s11060-015-1774-5
139 sgo:license sg:explorer/license/
140 sgo:sdDataset articles
141 rdf:type schema:ScholarlyArticle
142 N071e1bca21494030a33a65ca7375f10b schema:name dimensions_id
143 schema:value pub.1018898395
144 rdf:type schema:PropertyValue
145 N12f775eee3824484ab99b33ed1456215 rdf:first sg:person.013375073077.30
146 rdf:rest N42541b5f004f42bf8477c1d4a9244eb9
147 N14276f34da4847598b63ca638e76fbad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Middle Aged
149 rdf:type schema:DefinedTerm
150 N15478276d80347f9bbcbe437e9da903a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Male
152 rdf:type schema:DefinedTerm
153 N1b6fdc5430094b1facc356b00ede3dfb rdf:first sg:person.010260560177.95
154 rdf:rest Ncc704f483b58489490665a475127af5f
155 N26342b2c745a47498f761c7393b7395b schema:name doi
156 schema:value 10.1007/s11060-015-1774-5
157 rdf:type schema:PropertyValue
158 N2f528f55a3584fba83dbafa2490cd4c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Retrospective Studies
160 rdf:type schema:DefinedTerm
161 N361d316fe14142dbbe132728e5de428f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Neoplasm Staging
163 rdf:type schema:DefinedTerm
164 N3c201564abc848dda8d27345e059b373 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Female
166 rdf:type schema:DefinedTerm
167 N3ecdf3c88da34d499f82a371e789882e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Glioblastoma
169 rdf:type schema:DefinedTerm
170 N3f6f08b1fc654547813e6f78c253097d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Humans
172 rdf:type schema:DefinedTerm
173 N42541b5f004f42bf8477c1d4a9244eb9 rdf:first sg:person.01071535250.43
174 rdf:rest N1b6fdc5430094b1facc356b00ede3dfb
175 N48c930dd861a428ab74fac7148ae53d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Follow-Up Studies
177 rdf:type schema:DefinedTerm
178 N4dd73f8438eb41578917d565d0eb50e5 schema:name pubmed_id
179 schema:value 25894594
180 rdf:type schema:PropertyValue
181 N50fcc5de88de4ea1adeb039beca7e93f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Brain Neoplasms
183 rdf:type schema:DefinedTerm
184 N540b69c23e434c1d91efb0e0a74a3cfa schema:volumeNumber 123
185 rdf:type schema:PublicationVolume
186 N568c761cf6e24ab5a3ff5faf12ef739e rdf:first sg:person.01013322710.32
187 rdf:rest N12f775eee3824484ab99b33ed1456215
188 N608eeb3184734bb5a88c1e6aac40a8d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Prognosis
190 rdf:type schema:DefinedTerm
191 N6a192e25b2b44dce9781ac840bbe8125 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Aged
193 rdf:type schema:DefinedTerm
194 N711ea13cd48a4ef48259072b91e50b46 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Immunoenzyme Techniques
196 rdf:type schema:DefinedTerm
197 N72a0936cae264bd49bd65f6a20f539ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Magnetic Resonance Imaging
199 rdf:type schema:DefinedTerm
200 N75f01a15587d40628242c76f0498cc0e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Chemoradiotherapy
202 rdf:type schema:DefinedTerm
203 N86636079bd784e47984652d7978c143b schema:issueNumber 1
204 rdf:type schema:PublicationIssue
205 N8edfb53422ef42fd98093d2feacb245c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Biomarkers, Tumor
207 rdf:type schema:DefinedTerm
208 Na0b8e0cbac88492f8b1a4890c93c36d3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
209 schema:name Disease Progression
210 rdf:type schema:DefinedTerm
211 Na989d2dd343441f69e01f7fd3142d855 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
212 schema:name Adult
213 rdf:type schema:DefinedTerm
214 Nac5d0a0ee33b4c53afafd7582210997b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
215 schema:name Survival Rate
216 rdf:type schema:DefinedTerm
217 Nac7d1e319e7b491ab992bd4396232c09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
218 schema:name Young Adult
219 rdf:type schema:DefinedTerm
220 Ncc704f483b58489490665a475127af5f rdf:first sg:person.01156403355.42
221 rdf:rest rdf:nil
222 Neb09d3aa1f504e87b462a1df8b92fe29 schema:name Springer Nature - SN SciGraph project
223 rdf:type schema:Organization
224 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
225 schema:name Medical and Health Sciences
226 rdf:type schema:DefinedTerm
227 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
228 schema:name Clinical Sciences
229 rdf:type schema:DefinedTerm
230 sg:grant.2420949 http://pending.schema.org/fundedItem sg:pub.10.1007/s11060-015-1774-5
231 rdf:type schema:MonetaryGrant
232 sg:grant.2438826 http://pending.schema.org/fundedItem sg:pub.10.1007/s11060-015-1774-5
233 rdf:type schema:MonetaryGrant
234 sg:journal.1094205 schema:issn 0167-594X
235 1573-7373
236 schema:name Journal of Neuro-Oncology
237 schema:publisher Springer Nature
238 rdf:type schema:Periodical
239 sg:person.01013322710.32 schema:affiliation grid-institutes:grid.486749.0
240 schema:familyName Melguizo-Gavilanes
241 schema:givenName Isaac
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013322710.32
243 rdf:type schema:Person
244 sg:person.010260560177.95 schema:affiliation grid-institutes:grid.240145.6
245 schema:familyName Hess
246 schema:givenName Kenneth R.
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010260560177.95
248 rdf:type schema:Person
249 sg:person.01071535250.43 schema:affiliation grid-institutes:grid.240145.6
250 schema:familyName Guha-Thakurta
251 schema:givenName Nandita
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071535250.43
253 rdf:type schema:Person
254 sg:person.01156403355.42 schema:affiliation grid-institutes:grid.261331.4
255 schema:familyName Puduvalli
256 schema:givenName Vinay K.
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156403355.42
258 rdf:type schema:Person
259 sg:person.013375073077.30 schema:affiliation grid-institutes:grid.240145.6
260 schema:familyName Bruner
261 schema:givenName Janet M.
262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013375073077.30
263 rdf:type schema:Person
264 sg:pub.10.1007/s00401-005-0023-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1019017045
265 https://doi.org/10.1007/s00401-005-0023-y
266 rdf:type schema:CreativeWork
267 sg:pub.10.1007/s10014-012-0109-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1012468803
268 https://doi.org/10.1007/s10014-012-0109-x
269 rdf:type schema:CreativeWork
270 sg:pub.10.1007/s11060-005-5262-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031267961
271 https://doi.org/10.1007/s11060-005-5262-1
272 rdf:type schema:CreativeWork
273 sg:pub.10.1007/s11060-006-9241-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1015983460
274 https://doi.org/10.1007/s11060-006-9241-y
275 rdf:type schema:CreativeWork
276 sg:pub.10.1007/s11060-007-9341-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000374634
277 https://doi.org/10.1007/s11060-007-9341-3
278 rdf:type schema:CreativeWork
279 sg:pub.10.1007/s11060-009-9809-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004320007
280 https://doi.org/10.1007/s11060-009-9809-4
281 rdf:type schema:CreativeWork
282 sg:pub.10.1007/s11060-009-9897-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030107392
283 https://doi.org/10.1007/s11060-009-9897-1
284 rdf:type schema:CreativeWork
285 sg:pub.10.1007/s11910-009-0035-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052174107
286 https://doi.org/10.1007/s11910-009-0035-4
287 rdf:type schema:CreativeWork
288 grid-institutes:grid.240145.6 schema:alternateName Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA
289 Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
290 Department of Radiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
291 schema:name Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA
292 Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
293 Department of Radiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
294 rdf:type schema:Organization
295 grid-institutes:grid.261331.4 schema:alternateName Division of Neuro-oncology, The Ohio State University Comprehensive Cancer Center, 320 W, 10th Ave, M410 Staling Loving Hall, 43210, Columbus, OH, USA
296 schema:name Division of Neuro-oncology, The Ohio State University Comprehensive Cancer Center, 320 W, 10th Ave, M410 Staling Loving Hall, 43210, Columbus, OH, USA
297 rdf:type schema:Organization
298 grid-institutes:grid.486749.0 schema:alternateName Neuro-Oncology Associates at Baylor Charles A. Sammons Cancer Center, 75246, Dallas, TX, USA
299 schema:name Neuro-Oncology Associates at Baylor Charles A. Sammons Cancer Center, 75246, Dallas, TX, USA
300 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...